News & Media

Recent updates from Arcutis.

December 22, 2021 Featured

FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

September 30, 2021 Featured

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

December 23, 2021

Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

December 16, 2021

Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

December 13, 2021

Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream

December 13, 2021

Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream

November 10, 2021

Arcutis to Present at Upcoming Investor Conference

November 4, 2021

Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

October 4, 2021

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

September 28, 2021

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

September 27, 2021

New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress

September 9, 2021

Arcutis to Present at Upcoming Investor Conferences

Media Resources

Roflumilast Foam: Phase 2 Trial for the Treatment of Seborrheic Dermatitis

The Impact of Seborrheic Dermatitis

New England Journal of Medicine, Infographic / Backgrounder, July 2020

Media Contact

Amanda Shelton

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download